BNF Guidelines for Sildenafil Safety Assessment
Contraindications According to BNF Guidance
The British National Formulary clearly outlines specific contraindications for sildenafil that healthcare providers must assess before prescribing. Patients taking nitrates in any form, including glyceryl trinitrate spray or isosorbide medications, cannot safely use sildenafil due to the risk of severe hypotension. The BNF also contraindicates sildenafil in patients with severe cardiovascular disease, recent myocardial infarction or stroke within six months, and severe hepatic impairment.
Drug Interactions and Safety Monitoring
The BNF emphasises careful monitoring when sildenafil is used alongside certain medications. Alpha-blockers used for prostate conditions may enhance the hypotensive effects of sildenafil, requiring dose adjustment or timing considerations. Patients taking antihypertensive medications may experience additive blood pressure lowering effects. Riociguat, used for pulmonary arterial hypertension, is absolutely contraindicated with sildenafil. CYP3A4 inhibitors such as ketoconazole, ritonavir, and erythromycin can increase sildenafil plasma concentrations, potentially requiring dose reduction.
Cardiovascular Risk Assessment
The BNF guidelines emphasise thorough cardiovascular assessment before initiating sildenafil treatment. Sexual activity itself carries cardiovascular demands, and healthcare providers must evaluate whether patients can safely engage in sexual activity before considering erectile dysfunction treatment. Patients with unstable angina, uncontrolled hypertension, or heart failure require careful evaluation. The BNF recommends considering whether patients' cardiovascular status allows for the increased cardiac demands associated with sexual activity.
Side Effects Profile and Management
Common side effects documented in the BNF include headache, facial flushing, dyspepsia, and nasal congestion, which typically occur in 10-15% of patients. These effects are generally mild to moderate and transient. The BNF notes that visual disturbances, including blue-tinged vision and increased light sensitivity, may occur but are usually temporary. Serious adverse events are rare but include priapism (prolonged erection lasting over four hours) and sudden vision or hearing loss, which require immediate medical attention.
Dosing Guidelines and Safety Considerations
BNF dosing recommendations emphasise starting with the lowest effective dose, typically 50mg, taken approximately one hour before sexual activity. The maximum recommended dose is 100mg, with no more than one dose per 24-hour period. Patients over 65 years or those with hepatic or renal impairment may require dose reduction to 25mg. The BNF notes that both branded Viagra and generic sildenafil contain the same active ingredient and follow identical dosing guidelines, allowing patients to choose between options based on preference and cost considerations.
Special Populations and Precautions
The BNF provides specific guidance for special patient populations. Elderly patients may experience increased drug exposure and should start with lower doses. Patients with mild to moderate hepatic impairment require dose adjustment, whilst those with severe impairment should not receive sildenafil. Renal impairment may also affect drug clearance, particularly in severe cases. The BNF emphasises that sildenafil is not indicated for women or children under 18 years for erectile dysfunction treatment.
